Last reviewed · How we verify

NCT05360069

Linear Stapler Versus Circular Stapler in Esophagojejunostomy

Recruiting now NA Last updated 2 April 2026
What this trial tests

NA trial testing Linear stapler in Postoperative Complications in 100 participants. Currently enrolling.

Timeline
1 January 2020
Primary endpoint
31 December 2028
31 December 2028

Quick facts

Lead sponsorNanchong Central Hospital
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment100
Start date1 January 2020
Primary completion31 December 2028
Estimated completion31 December 2028
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Nanchong Central Hospital

Who can join

Adults 18 to 90, any sex, with Postoperative Complications or Operative Time. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

With the development of stapler devices, various methods of esophagojejunostomy after laparoscopic total gastrectomy were evoluated. Which stapler is more advantageous has not been determined. At present, the most commonly used is linear stapler or Circular stapler in esophagojejunostomy. However, there is still a lack of reliable evidence for the selection of the two staplers. The purpose of this study is to explore the advantages of linear staper versus circular stapler in esophagojejunostomy for patients with gastric cancer who underwent total gastrectomy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Postoperative Complications

Currently open trials in the same condition.

Other Nanchong Central Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05360069.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing